Journal of Bone Metabolism  2014;21(3):223-226

doi:10.11005/jbm.2014.21.3.223

Intravenous Zoledronate for a Patient with Paget's Disease.

Ki Choul KIM 1

Affiliations

+expand

Keywords

Bone density conservation agents; Diphosphonates; Osteitis deformans

Country

Republic of Korea

Language

English

Abstract

Paget's disease (PD) of bone is characterized by increase of bone resorption by atypical osteoclasts, followed by rapid new bone formation resulting in a disorganized mosaic bone. Although the pathophysiology is not fully understood, bisphosphonate, which is a potent anti-resorptive agent for treatment of osteoporosis, have been the most effective agents available for the treatment of PD. We report a case of PD of bone in a 49-year-old woman patient, who was treated with intravenous zoledronate.